nivolumab
AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer
The results from a global phase 3 trial show the longest survival data ever reported in this setting
Bristol Myers Squibb announces new $2.3bn campus in the US
Texas has been chosen as the site for a new, state-of-the-art multi-modal manufacturing campus
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
The drug showed improvements in overall survival and progression-free survival in two cancers
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis
Sotyktu is the first TYK2 inhibitor approved for active psoriatic arthritis
BMS announces affordable drug price agreement with US government
The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients
Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year
BMS granted FDA priority review for Breyanzi in marginal zone lymphoma
The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases
BMS and Bain Capital launch new company to develop immunology therapies
The newly formed company has in-licensed five investigational immunology drugs from BMS